Spain
· Delayed Price · Currency is EUR Pangaea Oncology Statistics
Total Valuation
Pangaea Oncology has a market cap or net worth of EUR 53.66 million. The enterprise value is 55.24 million.
| Market Cap | 53.66M |
| Enterprise Value | 55.24M |
Important Dates
The next estimated earnings date is Tuesday, October 29, 2024.
| Earnings Date | Oct 29, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
Pangaea Oncology has 30.14 million shares outstanding. The number of shares has decreased by -0.43% in one year.
| Shares Outstanding | 30.14M |
| Shares Change (YoY) | -0.43% |
| Shares Change (QoQ) | -0.42% |
| Owned by Insiders (%) | n/a |
| Owned by Institutions (%) | n/a |
| Float | 7.92M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 5.39 |
| PB Ratio | 3.01 |
| P/FCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -11.86 |
| EV / Sales | 5.55 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | -20.82 |
Financial Position
The company has a current ratio of 1.34, with a Debt / Equity ratio of 17.99.
| Current Ratio | 1.34 |
| Quick Ratio | 1.27 |
| Debt / Equity | 17.99 |
| Debt / EBITDA | n/a |
| Debt / FCF | -1.28 |
| Interest Coverage | -25.71 |
Financial Efficiency
Return on equity (ROE) is -22.89% and return on invested capital (ROIC) is -9.02%.
| Return on Equity (ROE) | -22.89% |
| Return on Assets (ROA) | -7.52% |
| Return on Capital (ROIC) | -9.02% |
| Revenue Per Employee | 66,811 |
| Profits Per Employee | -31,251 |
| Employee Count | 149 |
| Asset Turnover | 0.35 |
| Inventory Turnover | 5.05 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +212.93% in the last 52 weeks. The beta is 0.07, so Pangaea Oncology's price volatility has been lower than the market average.
| Beta (5Y) | 0.07 |
| 52-Week Price Change | +212.93% |
| 50-Day Moving Average | 1.48 |
| 200-Day Moving Average | 1.47 |
| Relative Strength Index (RSI) | 99.87 |
| Average Volume (20 Days) | 1,082 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Pangaea Oncology had revenue of EUR 9.95 million and -4.66 million in losses. Loss per share was -0.15.
| Revenue | 9.95M |
| Gross Profit | 7.56M |
| Operating Income | -3.44M |
| Pretax Income | -3.51M |
| Net Income | -4.66M |
| EBITDA | -2.69M |
| EBIT | -3.44M |
| Loss Per Share | -0.15 |
Balance Sheet
The company has 2.79 million in cash and 3.38 million in debt, giving a net cash position of -593,314 or -0.02 per share.
| Cash & Cash Equivalents | 2.79M |
| Total Debt | 3.38M |
| Net Cash | -593,314 |
| Net Cash Per Share | -0.02 |
| Equity (Book Value) | 18.81M |
| Book Value Per Share | 0.59 |
| Working Capital | 2.46M |
Cash Flow
In the last 12 months, operating cash flow was -2.40 million and capital expenditures -256,021, giving a free cash flow of -2.65 million.
| Operating Cash Flow | -2.40M |
| Capital Expenditures | -256,021 |
| Free Cash Flow | -2.65M |
| FCF Per Share | -0.09 |
Margins
Gross margin is 75.92%, with operating and profit margins of -34.59% and -46.78%.
| Gross Margin | 75.92% |
| Operating Margin | -34.59% |
| Pretax Margin | -35.22% |
| Profit Margin | -46.78% |
| EBITDA Margin | -27.07% |
| EBIT Margin | -34.59% |
| FCF Margin | -26.66% |
Dividends & Yields
Pangaea Oncology does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | 0.43% |
| Shareholder Yield | 0.43% |
| Earnings Yield | -8.68% |
| FCF Yield | -4.95% |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |